ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2026
LC-ESI-TOF-MS profiling and protective effects of Psidium cattleianum extract against gentamicin-induced nephrotoxicity in rats via Nrf2/HO-1 and caspase-dependent pathway.
Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug-induced nephrotoxicity is an alarming trigger for kidney injury. It is linked to a high rate of illness and fatality, with limited treatment options. Herein, we aimed to unravel the phytochemical profile and understand the protective activity of the aqueous methanolic extract (AME) of P.cattleianum Sabine (Myrtaceae) aerial parts against nephrotoxicity induced by gentamicin (GNT) in rats for the first time. The extract was chromatographed and analyzed using an LC-ESI-TOF-MS system. For the in vivo model, rats received the AME at doses of 200, 400, and 800 mg/kg/day orally for 14 days. The phytochemical results revealed the tentative identification of ninety metabolites, including twelve phenolic acids, fifty-one flavonoids, one proanthocyanidine, one lignan, four coumarins, three terpenes, four organic acids, two stilbenes, seven sugar derivatives, and five miscellaneous compounds. At 800 mg/kg, the AME significantly reduced the KW/BW ratio by 14.7%, BUN by 45.2%, creatinine by 57.6%, and Kim-1 by 57.3%. Oxidative stress markers MDA and 8-OHdG were lowered by 47.5% and 67.4%, respectively, while antioxidant markers GSH and SOD increased by 2.7- and 2.6-fold. The AME also restored HO-1 (4.6-fold increase) and Nrf2 (92.2-fold increase, relative to the GNT-treated group), and suppressed TNF-α, IL-1β, and NF-κB by 53.3%, 64.7%, and 58.9%, respectively. Apoptosis was reduced (Bax ↓64%, cytochrome c ↓58.8%, Bcl-2 ↑threefold), with marked histological improvements confirming nephroprotection. In all, the AME is promoted as an alternative remedy for controlling nephrotoxicity triggered by GNT. However, quantifying and isolating the major constituents and validating the clinical safety are among our future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.